

S/N: 10/634,645


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rojas et al. Examiner: Unassigned
Serial No.: 10/634,645 Group Art Unit: 1645
Filed: August 5, 2003 Docket No.: 14507-44063
Title: Fusion Proteins with a Membrane Translocating Sequence and Methods
of Using Same to Inhibit an Immune Response

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2004.

By: 
Name: Tim Tingkang Xia


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet containing Certificate of Mailing
- ☒ Request for Corrected Filing Receipt (2 pages)
- ☒ Copy of Filing Receipt Showing Corrections (2 pages)
- ☒ Return postcard

MORRIS, MANNING & MARTIN, LLP
1600 Atlanta Financial Center
3343 Peachtree Road NE
Atlanta, Georgia 30326
404.495.3678
Customer No. 24728

By: 
Name: Tim Tingkang Xia
Reg. No.: 45,242
TX



10/634,645

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Rojas et al.	Examiner:	Unassigned
Serial No.:	10/634,645	Group Art Unit:	1645
Filed:	August 5, 2003	Docket No.:	14507-44063
Title:	Fusion Proteins with a Membrane Translocating Sequence and Methods of Using Same to Inhibit an Immune Response		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2004.

By: 

Name: Tim Tingkang Xia

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a photocopy of the filing receipt from the United States Patent and Trademark Office in the above-identified application showing requested corrections. The filing receipt is erroneous with respect to the title of the invention. Please delete the second "an" from the title of the invention shown on the filing receipt.

The title of the invention should appear as follows:


**"FUSION PROTEINS WITH A MEMBRANE TRANSLOCATING SEQUENCE
AND METHODS OF USING SAME TO INHIBIT AN IMMUNE RESPONSE"**

Correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.

Respectfully submitted,


MORRIS, MANNING & MARTIN, LLP

Date: March 18, 2004



Tim Tingkang Xia
Reg. No. 45,242
TTX

1600 Atlanta Financial Center
3343 Peachtree Road, N.E.
Atlanta, Georgia 30326-1044
Phone: 404-233-7000
Direct: 404-495-3678



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).